

## Rapidly Initiate Nonclinical Testing for Your COVID-19 Treatment

As the pharmaceutical industry battles SARS-CoV-2, securing the right partners who can deliver fast results has never been more important. Through our integrated nonclinical CRO solution, you can rapidly design and execute *in vitro* and *in vivo* studies to advance your program for COVID-19 related treatment regimens.

### Stay on Track in Our Travel-Restricted World

We serve as an integrated extension of your development team, with a collaborative, proactive approach to manage study design and conduct. For all studies, we have increased virtual oversight and communications with labs to ensure that timelines remain on track. On-site monitoring is being evaluated on a case-by-case basis. For studies where on-site monitoring is not possible (e.g. studies performed in BSL-3 labs), we are working closely with labs on alternative solutions to ensure study continuity.

### Select the Right Species for *In Vivo* Testing

Camargo Research Group provides access to labs with the following models, which are either established or under development for COVID-19 related studies:

Animal Species	Uses in COVID-19 Studies
Hamster	Useful to study viral replication
Ferret	Good for clinical disease research
hACE2 mice	Transgenic mice are very adaptable model and they develop mild cases of the disease
LCM and RSV mice and rats	Appropriate to study the immune response and lung pathologies caused by the virus

Not sure which animal species is right for your program? Read our [blog article](#) to learn more.

### About Camargo Pharmaceutical Services

Camargo is the leading global strategy, regulatory, and development partner for early-stage and emerging biotech companies. We specialize in complex development programs that require a customized approach to regulatory and development strategy. Through our integrated nonclinical CRO solution, we provide harmonized development execution support to advance your program into the clinic with speed and capital efficiency.

### In This Together: Camargo Response Efforts for COVID-19

Our team is honored to lend our expertise to those at the forefront of combating COVID-19. In addition to nonclinical solutions, our capabilities include development strategy, [EUA](#) (Emergency Use Authorization) submission preparation, and FDA interactions such as expedited pre-IND meetings.

### Contact Us to Learn More

Dr. Karl-Rudolf Erlemann, Vice President, BD & External Scientific Affairs  
+1 (514) 807-9315 ext 105  
[KRErlemann@CamargoPharma.com](mailto:KRErlemann@CamargoPharma.com)